Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 5:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 96 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Auto-injector Clear all

Conditions: Diabetes Mellitus, Type 2
Interventions: Lixisenatide (AVE0010), Pen auto-injector, Exenatide, Prefilled pen injector, Metformin; Drug · Device
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 639 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Comparing Bioavailability When Makena® is Administered in Healthy Post-menopausal Women
Interventions: Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL); Drug
Lead sponsor: AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 50 Years to 75 Years · Female only
Enrollment: 122 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 5
States / cities: Anaheim, California • DeLand, Florida • Miami, Florida + 2 more

Conditions: Migraine
Interventions: "Investigational"Auto-injector (sumatriptan succinate); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 10
States / cities: San Francisco, California • Stamford, Connecticut • Chicago, Illinois + 7 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Lixisenatide (AVE0010), Placebo, Pen auto-injector, Metformin; Drug · Device
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 484 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Hypogonadism
Interventions: Testosterone enanthate auto-injector; Combination Product
Lead sponsor: Antares Pharma Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Healthy Subjects
Interventions: Auto-injector with exenatide suspension, Syringe with exenatide suspension; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 3,052 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 2
States / cities: Tempe, Arizona • Lincoln, Nebraska

Conditions: Health, Subjective
Interventions: CT-P13 SC Auto-injector, CT-P13 SC Pre-filled Syringe; Biological
Lead sponsor: Celltrion; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 218 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Study Participants
Interventions: bimekizumab; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 121 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Glendale, California

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Placebo (for Alirocumab), Non-statin LMT, Diet Alone; Drug · Other
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 8
States / cities: Beverly Hills, California • Atlantis, Florida • Jacksonville, Florida + 5 more

Conditions: Status Epilepticus
Interventions: Midazolam, Seizalam; Combination Product · Drug
Lead sponsor: Rafa Laboratories; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Food Allergy, Anaphylaxis, Food Hypersensitivity, Food Allergy Peanut
Interventions: Epinephrine Auto-Injector 0.3 mg/0.3 mL, Epinephrine 0.3 mg intramuscular manual injection via a syringe and needle, IN-001 9.06 mg Sublingual Spray, IN-001 13.59 mg Sublingual Spray; Drug
Lead sponsor: Insignis Therapeutics, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Hypogonadism
Interventions: Testosterone enanthate auto-injector; Combination Product
Lead sponsor: Antares Pharma Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 3
States / cities: Birmingham, Alabama • New York, New York • Columbus, Ohio

Conditions: Influenza
Interventions: Auto-injector for IM/SC vaccine administration; Device
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2006
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Male Hypogonadism
Interventions: Testosterone Cypionate 75 mg, Testosterone cypionate 50 mg, Testosterone cypionate 100 mg; Drug
Lead sponsor: Amneal Pharmaceuticals, LLC; Industry
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 10
States / cities: Santa Monica, California • DeLand, Florida • Miami Lakes, Florida + 7 more

Conditions: Multiple Sclerosis
Interventions: ofatumumab with PRF, ofatumumab with AI; Combination Product
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 13
States / cities: Fullerton, California • Aurora, Colorado • Basalt, Colorado + 9 more

Conditions: Insulin Hypoglycemia, Type 1 Diabetes Mellitus, Severe Hypoglycemia
Interventions: G-Pen, Lilly Glucagon; Drug
Lead sponsor: Xeris Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 4
States / cities: Chula Vista, California • Walnut Creek, California • Atlanta, Georgia + 1 more

Conditions: Healthy
Interventions: LY3074828, LY3074828, Auto-injector (AI), Prefilled syringe (PFS); Biological · Drug · Device
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Hypoglycemia, Diabetes Mellitus, Type 1
Interventions: G-Pen (glucagon injection), Lilly Glucagon (glucagon injection [rDNA origin]); Drug
Lead sponsor: Xeris Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 6
States / cities: Birmingham, Alabama • Chula Vista, California • Escondido, California + 3 more

Conditions: Hypoactive Sexual Desire Disorder
Interventions: Bremelanotide, Placebo; Drug
Lead sponsor: Palatin Technologies, Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 714 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 87
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 78 more

Conditions: Hypogonadism
Interventions: QuickShot™ - 50 mg Treatment B, QuickShot™ - 100 mg Treatment A, Delatestryl 200 mg IM Treatment C; Drug
Lead sponsor: Antares Pharma Inc.; Industry
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Brookline, Massachusetts

Conditions: Hepatitis C, Chronic
Interventions: Autoinjector, Pre-filled syringe; Device
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 12
States / cities: Los Angeles, California • Bradenton, Florida • Orlando, Florida + 9 more

Conditions: Hypercholesterolemia
Interventions: Placebo (for alirocumab), Alirocumab, Statin; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 803 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 49
States / cities: Chandler, Arizona • Goodyear, Arizona • Carmichael, California + 46 more

Conditions: Relapsing Multiple Sclerosis
Interventions: Quadrivalent influenza vaccine, Ofatumumab, iDMT; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: Phoenix, Arizona • Hollywood, Florida • St Louis, Missouri

Conditions: Hypoactive Sexual Desire Disorder
Interventions: Bremelanotide, Placebo; Drug · Other
Lead sponsor: Palatin Technologies, Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 723 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 87
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 79 more

Search by objective public record fields.

GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin

Comparing Bioavailability When Preservative-free Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) is Administered as an Intramuscular Manual Injection or as a Subcutaneous Injection Using an Auto-injector in Healthy Post-menopausal Women

A Study to Assess an Auto-injector Being Used to Treat a Migraine Attack

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin

Pharmacokinetic Study of Subcutaneous Testosterone Enanthate

Autoinjector Device Assessment Study

CT-P13 (Infliximab) Subcutaneous Administration by Pre-filled Syringe and Auto-injector in Healthy Subjects

A Bioequivalence Study of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection Using an Autoinjector in Healthy Study Participants

Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)

Study of Midazolam in Healthy Adults

PK/PD Study of IN-001 Sublingual Spray in Healthy Adults

Safety of Subcutaneous Testosterone Enanthate in Adult Male Hypogonadism

Pharma-Pen (Formerly Innoject) Auto-injectory TIV

Safety and Efficacy of Weekly Testosterone Cypionate Auto-Injector in Men With Hypogonadism

A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients

G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes

A Study of Two Formulations of LY3074828 in Healthy Participants

Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics

2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder

Pharmacokinetic Study of Testosterone Enanthate

A Study of Administration of Peginterferon Alfa-2a [Pegasys] by Autoinjector Versus Pre-filled Syringe in Patients With Chronic Hepatitis C

Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)

A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder